Liquidia Corporation to Present at BofA Securities 2025 Health Care Conference
Rhea-AI Summary
Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary disease treatments, will participate in the BofA Securities 2025 Health Care Conference. The company's CFO/COO Michael Kaseta and CMO Rajeev Saggar will deliver a business update in a fireside chat on May 13, 2025, at 1:40 PM PT / 4:40 PM ET in Las Vegas. Investors can access the webcast through Liquidia's website, where a recording will remain available for at least 30 days after the event.
Positive
- None.
Negative
- None.
MORRISVILLE, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the company’s Chief Financial Officer and Chief Operating Officer, Michael Kaseta, and Chief Medical Officer, Rajeev Saggar, will provide a business update during a fireside chat at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, beginning at 1:40 p.m. PT / 4:40 p.m. ET in Las Vegas, Nevada.
Access to a webcast will be available to investors and other interested parties by accessing Liquidia’s website at https://liquidia.com/investors/events-and-presentations.
An archived, recorded version of the presentation will be available on Liquidia’s website for at least 30 days following the event.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Contact Information
Investors:
Jason Adair
Chief Business Officer
919.328.4350
jason.adair@liquidia.com
Media:
Patrick Wallace
Director, Corporate Communications
919.328.4383
patrick.wallace@liquidia.com
FAQ
When is Liquidia Corporation (LQDA) presenting at the BofA Securities Health Care Conference 2025?
Who will represent LQDA at the BofA Securities 2025 Healthcare Conference?
How can investors access Liquidia's presentation at the BofA Securities conference?
How long will the recording of LQDA's presentation be available?
